
Innate Pharma S.A. IPHA
€ 1.15
-2.92%
Geschäftsbericht 2024
hinzugefügt 21.03.2026
Innate Pharma S.A. Current Ratio 2011-2026 | IPHA
Current Ratio Jährlich Innate Pharma S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2.03 | 2.18 | 1.59 | 1.51 | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.18 | 1.51 | 1.83 |
Current Ratio anderer Aktien in der Pharmaeinzelhändler
| Name | Current Ratio | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.02 | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
28.7 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
1.6 | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
2.39 | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
8.96 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.59 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
0.922 | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
7.98 | - | 10.36 % | $ 9.8 M | ||
|
Biophytis SA
BPTS
|
1.34 | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
0.889 | $ 217.23 | -0.38 % | $ 5 B | ||
|
Aurinia Pharmaceuticals
AUPH
|
4.41 | $ 13.92 | -4.4 % | $ 1.87 B | ||
|
Midatech Pharma plc
MTP
|
2.29 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.02 | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.94 | $ 19.22 | -0.05 % | $ 898 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.79 | - | - | $ 26.5 M | ||
|
AgeX Therapeutics
AGE
|
1.81 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
1.61 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
13.4 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.04 | - | - | - | ||
|
Coherus BioSciences
CHRS
|
1.31 | $ 1.65 | 0.61 % | $ 193 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
3.57 | $ 0.66 | 9.41 % | $ 7.56 M | ||
|
Adverum Biotechnologies
ADVM
|
1.65 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
0.41 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
5.93 | - | -9.65 % | $ 45.9 M | ||
|
CytomX Therapeutics
CTMX
|
2.88 | $ 4.26 | -4.48 % | $ 588 M | ||
|
Avenue Therapeutics
ATXI
|
3.27 | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
2.2 | $ 1.41 | 0.36 % | $ 360 M | ||
|
Ayala Pharmaceuticals
AYLA
|
6.43 | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
3.05 | - | - | $ 3.74 B | ||
|
Exelixis
EXEL
|
4.16 | $ 41.18 | -0.56 % | $ 11.2 B | ||
|
Aytu BioScience
AYTU
|
1.47 | $ 2.63 | - | $ 16.5 M | ||
|
Atreca
BCEL
|
2.02 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
2.37 | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
12.4 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
2.47 | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
2.14 | - | 0.49 % | $ 251 B | ||
|
Fulcrum Therapeutics
FULC
|
21.2 | $ 6.71 | -2.61 % | $ 425 K | ||
|
Genmab A/S
GMAB
|
15 | $ 25.65 | -0.14 % | $ 16.3 B | ||
|
Bellerophon Therapeutics
BLPH
|
1.47 | - | -74.18 % | $ 955 K | ||
|
Grifols, S.A.
GRFS
|
1.67 | $ 7.7 | 0.07 % | $ 6.83 B | ||
|
Akero Therapeutics
AKRO
|
10.9 | - | - | $ 3.67 B | ||
|
Halozyme Therapeutics
HALO
|
1.02 | $ 62.24 | -0.99 % | $ 7.46 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
5.24 | $ 4.25 | -3.96 % | $ 814 M | ||
|
Akouos
AKUS
|
6.18 | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
6.48 | - | 1.93 % | $ 17.4 M | ||
|
Immatics N.V.
IMTX
|
2.45 | $ 9.35 | -1.74 % | $ 588 M | ||
|
Allakos
ALLK
|
3.26 | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
5.28 | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
2.19 | - | 3.16 % | $ 1.9 M | ||
|
Calithera Biosciences
CALA
|
4.13 | - | -10.95 % | $ 876 K |